Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Top Cited Papers
- 21 December 2009
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (2), 121-128
- https://doi.org/10.1016/s1470-2045(09)70364-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical TrialsClinical Cancer Research, 2009
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III StudiesThe Oncologist, 2009
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)British Journal of Cancer, 2008
- A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung CancerThe Journal of Molecular Diagnostics, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003